Genomic and in vivo evidence of synergy of a herbal extract compared to its most active ingredient: Rabdosia rubescens vs. oridonin

Wong,Angela  M.; Zhang,Yanjung; Kesler,Kelly; Deng,Max; Burhenn,Lucas; Wang,David; Moro,Aune; Li,Zhaoping; Heber,David

doi:10.3892/etm.2010.145

Genomic and in vivo evidence of synergy of a herbal extract compared to its most active ingredient: Rabdosia rubescens vs. oridonin

Authors:
- Angela M. Wong
- Yanjung Zhang
- Kelly Kesler
- Max Deng
- Lucas Burhenn
- David Wang
- Aune Moro
- Zhaoping Li
- David Heber
View Affiliations

Affiliations: David Geffen School of Medicine, Center for Human Nutrition, University of California, Los Angeles, CA 90095, USA
Published online on: September 1, 2010 https://doi.org/10.3892/etm.2010.145
Pages: 1013-1017

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Rabdosia rubescens is a herbal root extract of traditional Chinese medicine (TCM) used to treat inflammatory diseases and oral cancers. A key principle of TCM is that multiple ingredients in a plant extract are more effective and less toxic than a single purified active ingredient or a purified drug derived from a plant product. Rabdosia rubescens extract (RRE) contains terpenoids and flavonoids, but the most active ingredient within the extract attributed to the inhibition of cancer is the kaurene diterpene, oridonin. In order to research synergy with a complete plant extract, the effects of RRE on the inhibition of prostate cancer cell proliferation were compared to the effects of pure oridonin alone in vitro. Three groups of 8 SCID mice bearing human prostate cancer xenografts (LAPC-4) were administered either RRE containing 0.02 mg/g oridonin, pure oridonin at a dose of 0.02 mg/g, or pure oridonin at a dose of 0.1 mg/g, by gavage for 5 days/week for 4 weeks. RRE and pure oridonin at 0.1 mg/g inhibited tumor growth to a similar extent, while oridonin at a dose of 0.02 mg/g did not. Therefore, in comparison to RRE, five times more pure oridonin was required to obtain equivalent prostate xenograft growth inhibition. Since the nuclear factor-κB signaling pathway and inflammation are implicated in prostate carcinogenesis, gene microarray analysis was conducted and demonstrated activation of genes by RRE that was not evident with oridonin treatment alone. This study demonstrated that genomic methods and xenograft studies are capable of demonstrating the benefits of the synergy of whole plant extracts rather than active ingredients isolated and purified as drugs.

View Figures

View References

1.	National Policy on Traditional Medicine and Regulation of Herbal Medicines: Report of a WHO Global Survery. WHO Press; Geneva: 2005
2.	Hong MY, Seeram NP, Zhang Y and Heber D: Chinese red yeast rice versus lovastatin effects on prostate cancer cells with and without androgen receptor overexpression. J Med Food. 11:657–666. 2008. View Article : Google Scholar : PubMed/NCBI
3.	Hong MY, Seeram NP, Zhang Y and Heber D: Anticancer effects of Chinese red yeast rice versus monacolin K alone on colon cancer cells. J Nutr Biochem. 19:448–458. 2008. View Article : Google Scholar : PubMed/NCBI
4.	Li Z, Seeram NP, Lee R, Thames G, Minutti C, Wang HJ and Heber D: Plasma clearance of lovastatin versus chinese red yeast rice in healthy volunteers. J Altern Complement Med. 11:1031–1038. 2005. View Article : Google Scholar : PubMed/NCBI
5.	Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM and Go VL: Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr. 69:231–236. 1999.PubMed/NCBI
6.	Halbert SC, French B, Gordon RY, Farrar JT, Schmitz K, Morris PB, Thompson PD, Rader DJ and Becker DJ: Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol. 105:198–204. 2010. View Article : Google Scholar : PubMed/NCBI
7.	Seeram NP, Adams LS, Hardy ML and Heber D: Total cranberry extract versus its phytochemical constituents: antiproliferative and synergistic effects against human tumor cell lines. J Agric Food Chem. 52:2512–2517. 2004. View Article : Google Scholar
8.	Seeram NP, Adams LS, Henning SM, Niu Y, Zhang Y, Nair MG and Heber D: In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem. 16:360–367. 2005. View Article : Google Scholar
9.	Henning SM, Niu Y, Liu Y, Lee NH, Hara Y, Thames GD, Minutti RR, Carpenter CL, Wang H and Heber D: Bioavailability and antioxidant effect of epigallocatechin gallate administered in purified form versus as green tea extract in healthy individuals. J Nutr Biochem. 16:610–616. 2005. View Article : Google Scholar : PubMed/NCBI
10.	Adams LS, Seeram NP, Hardy ML, Carpenter C and Heber D: Analysis of the interactions of botanical extract combinations against the viability of prostate cancer cell lines. Evid Based Complement Alternat Med. 3:117–124. 2006. View Article : Google Scholar : PubMed/NCBI
11.	Ikezoe T, Chen SS, Tong XJ, Heber D, Taguchi H and Koeffler HP: Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int J Oncol. 23:1187–1193. 2003.PubMed/NCBI
12.	Hsieh TC, Wijeratne EK, Liang JY, Gunatilaka AL and Wu JM: Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens. Biochem Biophys Res Commun. 337:224–231. 2005. View Article : Google Scholar : PubMed/NCBI
13.	Sartippour MR, Seeram NP, Heber D, Hardy M, Norris A, Lu Q, Zhang L, Lu M, Rao JY and Brooks MN: Rabdosia rubescens inhibits breast cancer growth and angiogenesis. Int J Oncol. 26:121–127. 2005.
14.	Ikezoe T, Yang Y, Bandobashi K, Saito T, Takemoto S, Machida H, Togitani K, Koeffler HP and Taguchi H: Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol Cancer Ther. 4:578–586. 2005.
15.	Hu HZ, Yang YB, Xu XD, Shen HW, Shu YM, Ren Z, Li XM, Shen HM and Zeng HT: Oridonin induces apoptosis via PI3K/Akt pathway in cervical carcinoma HeLa cell line. Acta Pharmacol Sin. 28:1819–1826. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Ren KK, Wang HZ, Xie LP, Chen DW, Liu X, Sun J, Nie YC and Zhang RQ: The effects of oridonin on cell growth, cell cycle, cell migration and differentiation in melanoma cells. J Ethnopharmacol. 103:176–180. 2006. View Article : Google Scholar : PubMed/NCBI
17.	Wang HJ, Li D, Yang FY, Tashiro S, Onodera S and Ikejima T: Oridonin induces human melanoma A375-S2 cell death partially through inhibiting insulin-like growth factor 1 receptor signaling. J Asian Nat Prod Res. 10:787–798. 2008.PubMed/NCBI
18.	Zhang CL, Wu LJ, Tashiro S, Onodera S and Ikejima T: Oridonin induced A375-S2 cell apoptosis via bax-regulated caspase pathway activation, dependent on the cytochrome c/caspase-9 apoptosome. J Asian Nat Prod Res. 6:127–138. 2004. View Article : Google Scholar : PubMed/NCBI
19.	Chen S, Gao J, Halicka HD, Huang X, Traganos F and Darzynkiewicz Z: The cytostatic and cytotoxic effects of oridonin (Rubescenin), a diterpenoid from Rabdosia rubescens, on tumor cells of different lineage. Int J Oncol. 26:579–588. 2005.PubMed/NCBI
20.	Zhang Y, Wu Y, Wu D, Tashiro S, Onodera S and Ikejima T: NF-kappa B facilitates oridonin-induced apoptosis and autophagy in HT1080 cells through a p53-mediated pathway. Arch Biochem Biophys. 489:25–33. 2009. View Article : Google Scholar : PubMed/NCBI
21.	Zhang CL, Wu LJ, Zuo HJ, Tashiro S, Onodera S and Ikejima T: Cytochrome c release from oridonin-treated apoptotic A375-S2 cells is dependent on p53 and extracellular signal-regulated kinase activation. J Pharmacol Sci. 96:155–163. 2004. View Article : Google Scholar : PubMed/NCBI
22.	Liu YQ, You S, Tashiro S, Onodera S and Ikejima T: Activation of phosphoinositide 3-kinase, protein kinase C, and extracellular signal-regulated kinase is required for oridonin-enhanced phagocytosis of apoptotic bodies in human macrophage-like U937 cells. J Pharmacol Sci. 98:361–371. 2005. View Article : Google Scholar
23.	Wagner H and Ulrich-Merzenich G: Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine. 16:97–110. 2009. View Article : Google Scholar : PubMed/NCBI
24.	Ulrich-Merzenich G, Panek D, Zeitler H, Wagner H and Vetter H: New perspectives for synergy research with ‘omic’ technologies. Phytomedicine. 16:495–508. 2009.